 |
 |
 |
| May 14, 2002 |
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara), and the Procter & Gamble Company (P&G, Headquarters: United States) signed an agreement today that transferred P&G’s business for Vicks Medicated Drops, a sore throat remedy in lozenge form, to Taisho, and made Taisho the exclusive sales agent of cold remedy Vicks VapoRub. Outline of Agreement (1) Taisho will acquire a license for an indefinite period for P&G’s Vicks Medicated Drops. The amount of the purchase has not yet been disclosed. Manufacture of the product will be consigned to P&G for the foreseeable future. (2) Taisho will carry out sales of Vicks VapoRub for P&G as the exclusive sales agent in Japan. By augmenting its lineup with the Vicks brand, which has a history of nearly 50 years at the top position in the Japanese OTC market, Taisho expects to bolster its Self-Medication Operation Group. Taisho has set a fiscal 2003 sales target of ¥2.0 billion for the Vicks brand. This deal is limited to Japan, and P&G will continue to conduct its $1.0 billion a year Vicks business, the second largest in the global OTC drug market. Daiwa Securities SMBC Co. Ltd. served as the adviser for the purchase agreement. |
||||||||||||||||||||||||
Product Information [Vicks Medicated Drops]
[Vicks VapoRub]
|
 |
